NICE Confirms AGNSS Positive Assessment that Eculizumab (SolirisÂ®) is a Very Effective Treatment for aHUS Patients and Produces Substantial Quality-Adjusted Life Year Gains of a Magnitude Rarely Seen for a New Drug